Belmont Capital’s AbbVie ABBV Stock Holding History

Belmont Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$505K	Hold	2,718	–	–	0.08%	72
2025 Q1	$569K	Sell	2,718 -4,023	-60%	-$782K	0.1%	59
2024 Q4	$1.2M	Hold	6,741	–	–	0.19%	34
2024 Q3	$1.33M	Buy	6,741 +481	+8%	+$89.8K	0.22%	36
2024 Q2	$1.07M	Buy	6,260 +612	+11%	+$101K	0.2%	43
2024 Q1	$1.03M	Buy	5,648 +5,528	+4,607%	+$953K	0.28%	38
2023 Q4	$18.6K	Sell	120 -548	-82%	-$79.9K	0.01%	129
2023 Q3	$99.6K	Buy	668 +500	+298%	+$73.4K	0.05%	91
2023 Q2	$22.6K	Buy	168 +120	+250%	+$17.6K	0.01%	96
2023 Q1	$7.65K	Hold	48	–	–	0.01%	112
2022 Q4	$8K	Hold	48	–	–	0.01%	107
2022 Q3	$6K	Buy	+48	New	+$6.89K	0.01%	102

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Belmont Capital's ABBV Position: Q2 2025 in Review

Belmont Capital held its AbbVie (ABBV) position steady in Q2 2025 at 2,718 shares worth $505K. The position accounts for 0.08% of the portfolio, ranked #72.

Belmont Capital first reported a position in ABBV in Q3 2022 and has held it in 12 quarters since. The position peaked at $1.33M in Q3 2024. 3,781 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

Belmont Capital held 2,718 shares of AbbVie worth $505K as of Q2 2025.
Belmont Capital left its AbbVie share count unchanged in Q2 2025.
AbbVie made up 0.08% of Belmont Capital's portfolio in Q2 2025, its #72 holding.
Belmont Capital first reported a position in AbbVie in Q3 2022 and has held it in 12 quarters since.
Belmont Capital's AbbVie position peaked at $1.33M in Q3 2024.
3,781 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on Belmont Capital's 13F filing for Q2 2025, filed 12 Aug 2025.